You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

199 Results
Guidelines and Advice
Status: Current
ID: 4-13
Version: 3
Mar 2022
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL 16-3
Version: 3
Mar 2022
Guidelines and Advice
Mar 2022
Guidelines and Advice
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Palliative
Funding:
Exceptional Access Program
    gilteritinib - Relapsed or Refractory FLT3-mutated acute myeloid leukemia
Mar 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Hairy Cell
Intent: Palliative
Mar 2022
Drug
Other Name(s): Lynparza®
Jan 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Jan 2025
Drug
Other Name(s): Padcev®
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Jan 2025
Drug
Other Name(s): Columvi®
Jan 2025

Pages